N-(2-溴丙基)邻苯二甲酰亚胺 | 21134-25-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: N-(2-溴丙基)邻苯二甲酰亚胺
• 英文名称: N-(2-bromopropyl)phthalimide
• 英文别名: 2-(2-bromopropyl)isoindole-1,3-dione
• CAS: 21134-25-8
• 化学式: C₁₁H₁₀BrNO₂
• 分子量: 268.11
• InChiKey: OEDMJTQRHMQBHD-UHFFFAOYSA-N

物化性质

• 沸点：
  347.6±25.0 °C(Predicted)
• 密度：
  1.575±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(2-溴丙基)邻苯二甲酰亚胺 在 氢溴酸 作用下， 生成 N-(溴丙基)邻苯二甲酰亚胺
  参考文献：
  名称：

  Boese, Chemische Berichte, 1920, vol. 53, p. 1995

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氢溴酸 作用下， 生成 N-(2-溴丙基)邻苯二甲酰亚胺
  参考文献：
  名称：

  Gabriel; Ohle, Chemische Berichte, 1917, vol. 50, p. 823

  摘要：

  DOI：

文献信息

• Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 ( NK-3 ) - and neurokinin 2 ( NK-3 ) receptor antagonists
  申请人：SmithKline Beecham S.p.A.

  公开号：US20020068827A1

  公开（公告）日：2002-06-06

  A compound of formula (I): 1 or a salt thereof, or a solvate thereof, wherein, Ar is an optionally substituted aryl or a C 5-7 cycloalkdienyl group, or an optionally substituted single or fused ring aromatic heterocyclic group; R is C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylalkyl, optionally substituted phenyl or phenyl C 1-6 alkyl, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatoms selected from O and N, hydroxy C 1-6 alkyl, amino C 1-6 alkyl, C 1-6 alkylaminoalkyl, di C 1-6 alkylaminoalkyl, C 1-6 acylaminoalkyl, C 1-6 alkoxyalkyl, C 1-6 alkylcarbonyl, carboxy, C 1-6 alkoxycarbonyl, C 1-6 alkoxycarbonyl C 1-6 alkyl, aminocarbonyl, C 1-6 alkylaminocarbonyl, di C 1-6 alkylaminocarbonyl, halogeno C 1-6 alkyl; or R is a group —(CH 2 ) p — wherein p is 2 or 3 which group forms a ring with a carbon atom of Ar; R 1 represents hydrogen or up to four optional subtitutents selected from the list consisting of: C 1-6 alkyl, C 1-6 alkenyl, aryl, C 1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C 1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino or mono- and di-C 1-6 alkylamino; R 2 represents hydrogen, C 1-6 -alkyl, hydroxy, halogen, cyano, amino, mono- or di-C 1-6 -alkylamino, alkylsulphonylamino, mono- or di-C 1-6 -alkanoylamino wherein any alkyl group is optionally substituted with an amino group or with a mono- or di-alkylamino group, or R 2 is a moiety —X—(CH 2 ) n —Y wherein X is a bond or —O— and n is an integer in the range of from 1 to 5 providing that when X is —O— n is only an integer from 2 to 5 and Y represents a group NY 1 Y 2 wherein Y 1 and Y 2 are independently selected from hydrogen, C 1-6 -alkyl, C 1-6 -alkenyl, aryl or aryl-C 1-6 -alkyl or Y is hydroxy, halogen or an optionally substituted N-linked single or fused ring, heterocyclic group, R 3 is branched or linear C 1-6 alkyl, C 3-7 cycloalkyl, C 4-7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring aromatic heterocyclic group; and R 4 represents hydrogen or C 1-6 alkyl; a process for the preparation of such a compound, a pharmaceutical compositon containing such a compound and the use of such a compound or composition in medicine.

  一个式为（I）的化合物： 或其盐，或其溶剂合物，其中，Ar是可选择取代的芳基或C 5-7 环烯烃基团，或可选择取代的单个或融合环芳香杂环基团； R是C 1-6 烷基，C 3-7 环烷基，C 3-7 环烷基烷基，可选择取代的苯基或苯基C 1-6 烷基，可选择取代的含有最多四个来自O和N的杂原子的五元杂芳环，羟基C 1-6 烷基，氨基C 1-6 烷基，C 1-6 烷基氨基烷基，二C 1-6 烷基氨基烷基，C 1-6 酰胺基烷基，C 1-6 烷氧基烷基，C 1-6 烷基羰基，羧基，C 1-6 烷氧羰基，C 1-6 烷氧羰基C 1-6 烷基，氨基羰基，C 1-6 烷基氨基羰基，二C 1-6 烷基氨基羰基，卤代C 1-6 烷基；或R是一个基团—(CH 2 ) p —其中p为2或3，该基团与Ar的一个碳原子形成环； R 1 代表氢或来自以下列表中选择的最多四个可选取代基：C 1-6 烷基，C 1-6 烯基，芳基，C 1-6 烷氧基，羟基，卤素，硝基，氰基，羧基，羧胺基，磺胺基，C 1-6 烷氧羰基，三氟甲基，酰氧基，邻苯二甲酰胺基，氨基或单-和双-C 1-6 烷基氨基； R 2 代表氢，C 1-6 -烷基，羟基，卤素，氰基，氨基，单-或双-C 1-6 -烷基氨基，烷基磺酰氨基，单-或双-C 1-6 -酰胺基，其中任何烷基基团可选择地取代为氨基基团或单-或双-烷基氨基基团，或R 2 是一个基团—X—(CH 2 ) n —Y，其中X是键或—O—，n是在1到5范围内的整数，要求当X为—O—时，n仅为2到5之间的整数，Y代表一个基团NY 1 Y 2 ，其中Y 1 和Y 2 分别选择自氢，C 1-6 -烷基，C 1-6 -烯基，芳基或芳基-C 1-6 -烷基，或Y为羟基，卤素或可选择取代的N-连接的单个或融合环杂环基团， R 3 是支链或直链C 1-6 烷基，C 3-7 环烷基，C 4-7 环烷基烷基，可选择取代的芳基，或可选择取代的单个或融合环芳香杂环基团；和 R 4 代表氢或C 1-6 烷基；一种制备这种化合物的方法，含有这种化合物的药物组合物以及这种化合物或组合物在医学中的用途。
• Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer
  作者：Mehdi Rajabi、Murat Yalcin、Shaker A. Mousa

  DOI：10.1016/j.bmcl.2018.02.045

  日期：2018.4

  (RGD) recognition site on the binding pocket of integrin αvβ3, tetraiodothyroacetic acid (tetrac, a deaminated derivative of T4) is a thyrointegrin receptor antagonist and blocks the actions of T3 and T4 as well as different growth factors-mediated angiogenesis. In this study, we synthesized novel tetrac analogs by modifying the phenolic moiety of tetrac and tested them for their anti-angiogenesis

  在血管生成过程中，整联蛋白是细胞表面跨膜受体家族的成员，在血管形成和血管生长因子的局部释放中起着至关重要的作用。甲状腺激素，例如升-thyroxine（T 4）和3,5,3'-三碘-升-甲腺氨酸（T 3），通过整合素αvβ3受体促进血管发生和肿瘤细胞增殖。处或附近的精氨酸-甘氨酸-天门冬氨酸上的整合素α结合口袋（RGD）的识别位点v β 3，tetraiodothyroacetic酸（tetrac，T的脱氨基衍生物4）是thyrointegrin受体拮抗剂和块T的动作3和第4以及不同的生长因子介导的血管生成。在这项研究中，我们通过修饰tetrac的酚部分合成了新颖的tetrac类似物，并使用用于小鼠血管生成的Matrigel栓塞模型测试了它们的抗血管生成活性。药理活性结果表明，tetrac可以适应多种修饰并保持其抗血管生成活性。
• PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS
  申请人：Beke Gyula

  公开号：US20090270411A1

  公开（公告）日：2009-10-29

  The present invention relates to new phenanthridine derivatives of formula (I), wherein the variables are as defined in the specification, to processes for producing the same, to pharmacological compositions containing the same and to their use in therapy or prevention of painful and inflammatory processes.

  本发明涉及公式（I）的新苯并喹啉衍生物，其中变量如规范中所定义，涉及制备这些衍生物的过程，包含这些衍生物的药理组合物以及它们在治疗或预防疼痛和炎症过程中的用途。
• PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS
  申请人：Beke Gyula

  公开号：US20100105686A1

  公开（公告）日：2010-04-29

  The present invention relates to new sulfonamide derivatives of formula (I) wherein R 1 -R 8 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these same compounds, pharmacological compositions containing them and to their use in therapy or prevention of painful and inflammatory conditions.

  本发明涉及式(I)的新磺酰胺衍生物，其中R1-R8和Z如权利要求中所定义，以及其光学对映体或外消旋体和/或盐和/或水合物和/或溶剂化物，它们是布雷地酮B1的选择性拮抗剂，用于制备这些化合物的方法、包含它们的药理学组合物以及它们在治疗或预防疼痛和炎症状况中的应用。
• SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS
  申请人：Bozo Eva

  公开号：US20100075978A1

  公开（公告）日：2010-03-25

  The present invention relates to new sulfonamide derivatives of formula (I) wherein R 1 -R 5 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these compounds, pharmacological compositions containing them and to their use in therapy or prevention of painful and inflammatory conditions.

  本发明涉及公式（I）的新型磺酰胺衍生物， 其中R1-R5和Z如权利要求中所定义，以及其光学对映体或外消旋体和/或盐和/或水合物和/或溶剂化物，它们是缓激肽B1的选择性拮抗剂，用于制备这些化合物的方法，包含它们的药理学组合物以及在治疗或预防疼痛和炎症状况中的使用。